Liver Diseases  >>  Daklinza (daclatasvir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

16 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daklinza (daclatasvir) / BMS
HEPCAT, NCT01125189 / 2010-018295-24: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Checkmark COMMAND-1
Aug 2014 - Aug 2014: COMMAND-1
Checkmark EASL 2013: COMMAND 1
Apr 2013 - Apr 2013: EASL 2013: COMMAND 1
Checkmark AASLD 2012: COMMAND-1
More
Completed
2b
558
US, Canada, Europe, RoW
Daclatasvir, Placebo, peg-interferon alfa-2a, Pegasys, ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
04/12
08/12
NCT01257204 / 2010-022408-28: Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Checkmark
Oct 2014 - Oct 2014: 
Checkmark AGW 2013: COMMAND GT2/3
Sep 2013 - Sep 2013: AGW 2013: COMMAND GT2/3
Checkmark EASL 2013: COMMAND GT2/3
More
Completed
2b
196
US, Canada, Europe, RoW
Placebo, Daclatasvir, BMS-790052, Pegylated interferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
05/12
09/12
HEPCAT, NCT01170962 / 2010-019378-34: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Completed
2b
512
US, Canada, Europe, RoW
BMS-790052, Placebo, peginterferon alfa-2a, Pegasys®, ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
06/12
12/12
NCT01629732: Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Withdrawn
2b
0
US
Daclatasvir, BMS-790052 (DCV), BMS-986094, Ribavirin, Copegus®, Placebo for BMS-986094
Bristol-Myers Squibb
Hepatitis C Virus
02/14
06/14
NCT00874770 / 2009-010149-29: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Checkmark Data-AASLD
Oct 2011 - Oct 2011: Data-AASLD
Checkmark Data
Mar 2011 - Mar 2011: Data
Completed
2a
74
US, Europe
Daclatasvir, Placebo, Peginterferon alpha-2a, Pegasys, ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Infection
11/09
01/11
NCT01016912: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Checkmark
Jan 2014 - Jan 2014: 
Checkmark
Jan 2014 - Jan 2014: 
Checkmark Data-AASLD
More
Completed
2a
51
Japan
BMS-790052, Placebo, Peginterferon alfa-2b, PegIntron®, Ribavirin, Rebetol®
Bristol-Myers Squibb
Hepatitis C Infection
09/10
09/10
NCT01017575: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Checkmark
Jan 2014 - Jan 2014: 
Checkmark
Jan 2014 - Jan 2014: 
Completed
2a
55
Japan
Daclatasvir, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Infection
10/11
10/11
NCT01359644: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Checkmark ACG 2014
Sep 2014 - Sep 2014: ACG 2014
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark EASL 2014
More
Completed
2
350
US
PSI-7977, Daclatasvir, BMS-790052, Ribavirin, Copegus ®
Bristol-Myers Squibb, Pharmasset
Chronic Hepatitis C
01/13
10/13
NCT01425970: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Terminated
2
210
US
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir, BMS-790052
Bristol-Myers Squibb
Hepatitis C
08/13
08/13
NCT01455090: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark CROI 2014
More
Completed
2
320
US, Europe
BMS-650032, Asunaprevir (ASV), BMS-790052, Daclatasvir (DCV), BMS-791325, Ribavirin, Copegus®
Bristol-Myers Squibb
Chronic Hepatitis C
03/14
07/15
NCT01842451: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark From 100mg and 200mg arms of 12-week combination therapy trial (VX-135+daclatasvir) in G1 hep C infected patients
Jan 2014 - Jan 2014: From 100mg and 200mg arms of 12-week combination therapy trial (VX-135+daclatasvir) in G1 hep C infected patients
Completed
2
23
RoW
VX-135, Daclatasvir
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C, CHC, HCV, Hepatitis C
05/14
05/14
NCT02107365: Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Completed
2
60
Europe
Asunaprevir, Daclatasvir, Ribavirin, Pegylated Interferon alpha-2a
ANRS, Emerging Infectious Diseases, Bristol-Myers Squibb
Hepatitis C Virus Genotype 4 Infection
02/15
04/15
NCT01938625 / 2013-002726-23: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Completed
2
35
Europe
Simeprevir, Daclatasvir, Ribavirin, Cyclosporine, Tacrolimus
Janssen R&D Ireland
Hepatitis C, Chronic
04/15
07/15
QUATTROTURBO, NCT02309450: Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

Withdrawn
2
0
Europe
.Asunaprevir, Daclatasvir and BMS - 791325
ANRS, Emerging Infectious Diseases, Bristol-Myers Squibb
Hepatitis C Virus Genotype 4 Infection
11/15
08/16
COMMIT, NCT02268864 / 2014-003413-28: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

Completed
2
106
Europe
Simeprevir, Daclatasvir
Janssen-Cilag International NV
Hepatitis C, Chronic
01/16
04/16
NCT00546715: A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Completed
1/2
95
US
Daclatasvir, Placebo
Bristol-Myers Squibb
Chronic Hepatitis C
05/08
05/08

Download Options